Zimberelimab

Phase 3

Gilead Sciences, Inc. (GILD)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

GILDPhase 3$187.5B

Zimberelimab Phase 3 Est. Readout

Zimberelimab• Head and Neck Squamous Cell Carcinoma1,021

Mar 2027~EstimatedSTALE

CT.gov

00%

Competitive Landscape

3 competitors in Head and Neck Squamous Cell Carcinoma

MRUSPetosemtamab

Phase 3

MRUSInvestigator's Choice

Drug Information

Target Indication

Head and Neck Squamous Cell Carcinoma

Clinical Trial

NCT06727565

Last updated: 2/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

StribildPhase 3

Acquired Immunodeficiency Syndrome

LenacapavirPhase 3

HIV Prevention

MagrolimabPhase 3

Myelodysplastic Syndrome

MTXPhase 3

Rheumatoid Arthritis

Sacituzumab Govitecan (SG)Phase 3

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts